Novartis (NVS) Excites Incyte (INCY) with Licensing Deal
Novartis (NYSE: NVS) and Incyte Corp. (NASDAQ: INCY) struck a licensing deal where Novartis will gain access to Incyte's therapies for caner patients and patients with blood-disorders that could be life-threatening.
Novartis agreed to pay Incyte $150 million upfront. The first milestone payment Incyte will receive could be up to $60 million.
Shares of Incyte are trading up 6.61% to $8.23. Novartis is up 0.85% to $55.78.
Create E-mail AlertRelated Categories
General NewsMomentum Movers
Stocks Mentioned
+0.00
-0.55Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
